Details of the Drug
General Information of Drug (ID: DMO2UKI)
Drug Name |
SP-MET-1
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms | S1004A receptor antagonist (cancer), Supratek; SP-MET-X1; Antimetastatic agent (oral, cancer), Supratek; S1004A receptor antagonist (oral, melanoma/breast/colorectal cancer), Supratek | ||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||